A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies.

Trial Profile

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2012

At a glance

  • Drugs Temsirolimus; Topotecan
  • Indications Gynaecological cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Apr 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 25 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top